CDK6 and Decreased total neutrophil count: The higher and more selective activity of abemaciclib against CDK4 than CDK6 (Figure 1, Supplementary Table 1), as well as the ratio of unbound Cmax to CDK6 potency, may explain the different rates of neutropenia observed among treatments [14].